174 related articles for article (PubMed ID: 20554995)
21. The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats.
Pollard M; Luckert PH
Cancer Lett; 1991 Aug; 59(2):159-63. PubMed ID: 1832081
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer.
Tiwari RK; Geliebter J; Garikapaty VP; Yedavelli SP; Chen S; Mittelman A
Int J Oncol; 1999 Apr; 14(4):713-9. PubMed ID: 10087319
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.
Pienta KJ; Naik H; Akhtar A; Yamazaki K; Replogle TS; Lehr J; Donat TL; Tait L; Hogan V; Raz A
J Natl Cancer Inst; 1995 Mar; 87(5):348-53. PubMed ID: 7853416
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
Behrakis P; Koutsilieris M
Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
[TBL] [Abstract][Full Text] [Related]
26. Hormone-refractory prostate cancer in the Lobund-Wistar rat.
Pollard M; Suckow MA
Exp Biol Med (Maywood); 2005 Sep; 230(8):520-6. PubMed ID: 16118401
[TBL] [Abstract][Full Text] [Related]
27. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
28. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
Jenkins DE; Oei Y; Hornig YS; Yu SF; Dusich J; Purchio T; Contag PR
Clin Exp Metastasis; 2003; 20(8):733-44. PubMed ID: 14713107
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone and prostate cancer growth and metastasis in tumor-bearing animals.
Torosian MH
J Pediatr Endocrinol; 1993; 6(1):93-7. PubMed ID: 8374696
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
[TBL] [Abstract][Full Text] [Related]
31. The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma.
Schleicher RL; Lamartiniere CA; Zheng M; Zhang M
Cancer Lett; 1999 Mar; 136(2):195-201. PubMed ID: 10355749
[TBL] [Abstract][Full Text] [Related]
32. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo.
Rabbani SA; Harakidas P; Guo Y; Steinman D; Davidsen SK; Morgan DW
Int J Cancer; 2000 Jul; 87(2):276-82. PubMed ID: 10861487
[TBL] [Abstract][Full Text] [Related]
33. Influence of linomide on local tumor growth and metastasis of the human hormone-resistant prostate cancer cell line PC3 in an orthotopic model.
Bex A; Luboldt H; Sudermann T; Rembrink K; Otto T; Rübben H
Eur Urol; 2000 May; 37(5):628-33. PubMed ID: 10765105
[TBL] [Abstract][Full Text] [Related]
34. [Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Roca Edreira A; Aguilera Tubet C; Villanueva Peña A; Ballestero Diego R; Zubillaga Guerrero S
Actas Urol Esp; 2007 Jun; 31(6):693-5; discussion 695. PubMed ID: 17896567
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of Lobund-Wistar x Copenhagen hybrid rats to autochthonous prostate carcinogenesis.
Suckow MA; Wolter W; Pollard M
Prostate; 2005 Jul; 64(2):203-8. PubMed ID: 15712219
[TBL] [Abstract][Full Text] [Related]
36. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Ray P; Bhatti R; Gadarowski J; Bell N; Nasruddin S
Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
[TBL] [Abstract][Full Text] [Related]
38. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
[TBL] [Abstract][Full Text] [Related]
39. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
[TBL] [Abstract][Full Text] [Related]
40. Effect of ascorbic acid on reactive oxygen species production in chemotherapy and hyperthermia in prostate cancer cells.
Fukumura H; Sato M; Kezuka K; Sato I; Feng X; Okumura S; Fujita T; Yokoyama U; Eguchi H; Ishikawa Y; Saito T
J Physiol Sci; 2012 May; 62(3):251-7. PubMed ID: 22392350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
